Abbott Introduces mView Automated Performance Monitoring Service for its m2000 Molecular Diagnostics System
Satisfies Unmet Customer Need for Automated Performance Reports
ABBOTT PARK, Ill., September 11, 2014 – Abbott has introduced worldwide a new, automated performance monitoring subscription, mView, for its widely used m2000 molecular diagnostics system. mView is designed to automate data analysis and help laboratories reduce the number of manually generated reports.
A survey of molecular diagnostics laboratory managers conducted by Abbott showed that they spent 15 percent of their time collecting data, organizing it, developing graphs and finally interrupting the information.
“We learned from our customers that automating instrument analytics into configurable reports will reduce the time spent by laboratory management and procurement to organize, analyze and visualize data. Displaying the data into actionable information improves the molecular lab operations and efficiency,” said Maarten van der Linden, marketing director, for Abbott’s molecular diagnostics business in Europe.
Deidre Burke, the Laboratory Manager at UCD National Virus Reference Laboratory in Dublin Ireland said, “We found the software intuitive, easy to use and allowed us to generate operational performance reports in a timely manner. The mView custom reports are well presented and contain extensive analytical information. This innovative software solution has expedited the retrieval and analysis of performance data in my laboratory by 80 percent.”
mView is web-based and will be marketed to existing and new Abbott m2000 customers. Installation of AbbottLink, Abbott’s remote diagnostics agent, provides access to the instrument analytics and is required before access to an mView subscription. mView customers will receive training via WebEx to navigate the website and create reports.
Features of mView include a dashboard for quick reference, several configurable reports, as well as monthly archived reports that monitor operational efficiencies including calibration frequency, tests over time, run efficiency and composition. Data are readily available and validated from m2000rt software screens or results logs. Patient information is not accessible via AbbottLink and mView. Abbott offers middleware solutions that allow access to patient test results.
About Abbott Molecular
Abbott Molecular is a leader in molecular diagnostics – the analysis of DNA and RNA at the molecular level. Abbott Molecular’s tests can also detect subtle but key changes in patients’ genes and chromosomes and have the potential to aid with early detection or diagnosis, can influence the selection of appropriate therapies, and may assist with monitoring of disease progression.
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000.
Abbott has been operating in Canada since 1931 and its Canadian operations are headquartered in Montreal, Quebec. Abbott Canada employs more than 2,000 people. Abbott’s news releases and other information are available on the company’s web sites at www.abbott.ca and www.abbott.com.
SOURCE: Abbott Molecular